Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab + nab-paclitaxel + lobaplatin neoadjuvant study in stage II-III triple-negative breast cancer
ChiCTR2400094426Phase 4Recruiting
- Sponsor
- Southwest Hospital of Army Medical University
- Start
- Dec 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ivonescimab, paclitaxel and lobaplatin in triple-negative breast cancer (TNBC), sponsored by Southwest Hospital of Army Medical University. Primary endpoint: Total pathological complete response. Started Dec 2024; status: recruiting.
02
Drugs
ivonescimabpaclitaxellobaplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2400094426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094426.